Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
akcea therapeutics
boston blog main
boston top stories
fda
4
×
inotersen
4
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
alnylam pharmaceuticals
boston
hereditary transthyretin amyloidosis
patisiran
san francisco blog main
san francisco top stories
tafamidis
biotech
clinical trials
drugs
onpattro
pfizer
rna interference
vyndaqel
2025
ad-comm
affimed
allogene therapeutics
amicus therapeutics
andrew fire
approval
apremilast
barry greene
base editing
bio
biogen
biome
blueprint medicineas
What
alnylam
fda
medicine
drug
rna
rnai
uses
afternoon
ago
allogene
alnylam’s
approve
approved
approves
awaits
bio
biological
cancer
cells
crispr
crossed
decades
decision
discovered
diversity
ema
employ
europe
fingers
follows
friday
gene
gets
harmful
historic
history
hits
hot
immunotherapy
interference
Language
Current search:
inotersen
×
fda
×
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision